Kymera Therapeutics (NASDAQ:KYMR) Given Overweight Rating at Stephens

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “overweight” rating reiterated by equities researchers at Stephens in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $60.00 price objective on the stock. Stephens’ price objective would indicate a potential upside of 35.96% from the company’s previous close.

KYMR has been the topic of a number of other reports. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. UBS Group dropped their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Morgan Stanley lifted their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.06.

Kymera Therapeutics Stock Up 1.0 %

Shares of KYMR opened at $44.13 on Tuesday. The company has a market cap of $2.86 billion, a P/E ratio of -18.86 and a beta of 2.19. Kymera Therapeutics has a fifty-two week low of $29.24 and a fifty-two week high of $53.27. The firm’s 50 day moving average price is $42.71 and its 200 day moving average price is $44.65.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.90) earnings per share. Research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC lifted its position in Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after purchasing an additional 368,394 shares during the period. Wellington Management Group LLP raised its stake in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after buying an additional 308,954 shares in the last quarter. FMR LLC lifted its holdings in shares of Kymera Therapeutics by 5.8% in the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after buying an additional 282,301 shares during the period. Driehaus Capital Management LLC purchased a new stake in shares of Kymera Therapeutics in the second quarter valued at approximately $6,669,000. Finally, Renaissance Technologies LLC acquired a new position in Kymera Therapeutics during the second quarter worth $4,271,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.